Figure 4. Oral administration of ZLN005 prevents cisplatin-induced AKI. The male C57BL/6 mice were injected once with cisplatin (16mg/kg, i.p.) to induce AKI, followed by ZLN005 treatment (15mg/kg/d, i.g.) for 4 days. (A) Serum BUN and Crea levels were quantified in each group (n=10). (B) Representative images of HE- and PAS-stained kidney sections. (C) Representative images of immunohistochemical staining using anti-Kim-1 and anti-PGC-1α antibodies. Scar bar: 20 μm. (D) Representative images of western blotting and the quantitative analysis of PGC-1α, Bax and Bcl-2. (E) Representative micrographs showing TUNEL staining. Data are provided as the mean ± SEM, n=3 independent experiments. *P < 0.05, **P < 0.01 vs. Con; &P < 0.05, &&P < 0.01 vs. Cisp. (NC, normal control; Cisp, cisplatin; C+Z, cisplatin + ZLN005).